改良吉西他滨作为晚期胰腺腺癌的二线治疗方案。
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
作者信息
Ajouz Hana, Mukherji Deborah, Haydar Ali, Yakan Ahmad Sharif, Saleh Ahmad, Elias Elias, Temraz Sally, Faraj Walid, Khalife Mohammad, Shamseddine Ali
机构信息
Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon,
出版信息
J Gastrointest Cancer. 2014 Mar;45(1):109-12. doi: 10.1007/s12029-013-9571-x.
BACKGROUND
Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy. Gemcitabine, docetaxel, and capecitabine (GTX) is a regimen that has come into use for advanced pancreatic cancer despite a paucity of randomized data.
METHODS
We have used a modified schedule of this regimen in the second-line setting aimed at biomodulating the activity of capecitabine by both docetaxel and gemcitabine. This report describes our experience with the use of modified GTX in nine patients with advanced pancreatic cancer as second-line chemotherapy.
CONCLUSION
In our series, the median overall survival was 8 months (range 5.2-10.8). Prospective studies of this regimen in the second-line setting are warranted.
背景
晚期胰腺癌仍然是一种致命疾病，除一线姑息化疗外没有标准治疗方法。吉西他滨、多西他赛和卡培他滨（GTX）方案尽管缺乏随机数据，但已用于晚期胰腺癌。
方法
我们在二线治疗中使用了该方案的改良方案，旨在通过多西他赛和吉西他滨对卡培他滨的活性进行生物调节。本报告描述了我们使用改良GTX方案对9例晚期胰腺癌患者进行二线化疗的经验。
结论
在我们的系列研究中，中位总生存期为8个月（范围5.2 - 10.8个月）。有必要对该方案在二线治疗中的应用进行前瞻性研究。
Zotero 插件